מודרנה היא חברת ביוטכנולוגיה אמריקאית פורצת דרך, אשר חרטה על דגלה את החדשנות והקידמה בתחום הרפואה. החברה, שנוסדה בשנת 2010, מתמקדת בפיתוח חיסונים ותרופות המבוססים על טכנולוגיית mRNA (RNA שליח) – טכנולוגיה מהפכנית המאפשרת לגוף לייצר חלבונים טיפוליים בעצמו. גישה חדשנית זו פותחת פתח לטיפול במגוון רחב של מחלות, החל ממחלות זיהומיות ועד לסרטן ומחלות אוטואימוניות.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here
- orshu
- •
- 6 Min Read
- •
- ago 1 minute
BIOGEN RAISES ANNUAL PROFIT FORECAST ON STRONG DEMAND FOR RARE DISEASE DRUGS
Biogen's Performance Driven by Rare Disease Drugs Biogen is seeing a significant boost in its financial performance due to
- ago 1 minute
- •
- 6 Min Read
Biogen's Performance Driven by Rare Disease Drugs Biogen is seeing a significant boost in its financial performance due to
- orshu
- •
- 8 Min Read
- •
- ago 1 hour
Americas Market Snapshot: Navigating Mixed Signals on July 31, 2025
Introduction As of Thursday, July 31, 2025, the Americas markets are presenting a mixed bag of performance, with some key
- ago 1 hour
- •
- 8 Min Read
Introduction As of Thursday, July 31, 2025, the Americas markets are presenting a mixed bag of performance, with some key
- Articles
- •
- 7 Min Read
- •
- ago 2 hours
Market Shrinks Appetite for Risk: Young Unprofitable Companies Hit a Multi-Year Low
Sharp Decline in YUCs’ Market Share Signals Shift Toward Profit Discipline As of June 30, 2025, young unprofitable companies—those with
- ago 2 hours
- •
- 7 Min Read
Sharp Decline in YUCs’ Market Share Signals Shift Toward Profit Discipline As of June 30, 2025, young unprofitable companies—those with
- Articles
- •
- 6 Min Read
- •
- ago 3 hours
Trump Strikes Trade Deal with South Korea: 15% Tariffs in Exchange for $350B in Investments
A strategic recalibration aiming to restore market confidence In a pivotal move on the global trade stage, former U.S. President
- ago 3 hours
- •
- 6 Min Read
A strategic recalibration aiming to restore market confidence In a pivotal move on the global trade stage, former U.S. President
